Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (106)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (275)
  2. Genitourinary Oncology Service (275)
  3. Solid Tumor Oncology Division (275)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Human Oncology and Pathogenesis Program (41)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (11)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (16)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (24)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (275)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): Prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)
    Meeting Abstract

    Efstathiou, E.; Attard, G.; Lucas, J.; Thomas, S.; Gormley, M.; Aguilar-Bonavides, C.; Flaig, T. W.; Franke, F.; Goodman, O. B.; Oudard, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial
    Journal Article

    Powles, T.; Yuen, K. C.; Gillessen, S.; Kadel, E. E. 3rd; Rathkopf, D.; Matsubara, N.; Drake, C. G.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply
    Correspondence

    Saad, F.; De Porre, P.; Brookman-May, S.; Li, J.; McCarthy, S. A.; Rathkopf, D. E.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for oligometastatic prostate cancer
    Journal Article

    Brennan, V.; Spektor, A.; Sweeney, C.; Choudhury, A.; Rathkopf, D.; Pomerantz, M.; Hertan, L.; Nguyen, P.; Martin, N.; Balboni, T.; more...
    Advances in Radiation Oncology (2022)

    Fulltext@MSK | Save
  • Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study
    Journal Article

    Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O. B. Jr; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O.; Oudard, S.; Steuber, T.; Suzuki, H.; Pieczonka, C. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT)
    Meeting Abstract

    De Bono, J. S.; Cook, N.; Yu, E. Y.; Lara, P. N.; Wang, J. S.; Yamasaki, Y.; Yamamiya, I.; Gao, P.; Calleja, E. M.; Rathkopf, D. E.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save